中国现代医学杂志2025，Vol.35Issue(9)：1-6,6.DOI:10.3969/j.issn.1005-8982.2025.09.001
替罗非班联合尼可地尔对急性心肌梗死PCI患者早期心绞痛的疗效及vWF、CD62P、GPⅡb/Ⅲa受体复合物的影响
The effect of tirofiban combined with nicorandil on early angina pectoris and levels of vWF,CD62P,and GPⅡb/Ⅲa receptor complex in patients with acute myocardial infarction treated by percutaneous coronary intervention
摘要
Abstract
Objective To investigate the clinical efficacy of tirofiban combined with nicorandil on early angina pectoris and its effects on von Willebrand factor(vWF),P-selectin(CD62P),and glycoprotein(GP)Ⅱb/Ⅲa receptor complex levels in acute myocardial infarction(AMI)patients undergoing percutaneous coronary intervention(PCI).Methods This prospective study enrolled 213 AMI patients treated with PCI at Daqing Longnan Hospital from January 2020 to August 2023,randomly assigned to either the observation group(n=107,receiving intracoronary tirofiban 10 μg/kg plus nicorandil 0.06 mg/kg)or control group(n=106,receiving tirofiban 10 μg/kg alone).We measured changes in vWF,CD62P,and GPⅡb/Ⅲa levels,recorded angina frequency/duration,assessed severity using the Seattle Angina Questionnaire(SAQ),and monitored adverse events.Results The observation group demonstrated significantly greater reductions in vWF,CD62P,and GPⅡb/Ⅲa levels compared to controls(all P<0.05).Angina frequency and duration decreased more substantially in the observation group(both P<0.05).SAQ scores showed greater improvement in physical limitation,angina stability,attack frequency,and treatment satisfaction(all P<0.05),though disease perception changes were comparable(P>0.05).Adverse event rates did not differ significantly between groups(P>0.05).Conclusion The tirofiban-nicorandil combination effectively reduces vWF/CD62P/GPⅡb/Ⅲa levels,decreases angina frequency,and improves symptoms in post-PCI AMI patients,suggesting superior clinical outcomes without increased adverse effects.关键词
急性心肌梗死/心绞痛/替罗非班/尼可地尔/经皮冠脉介入术Key words
myocardial infarction/angina pectoris/tirofiban/nicorandil/percutaneous coronary intervention分类
医药卫生引用本文复制引用
陆洋,李海兰,王珊..替罗非班联合尼可地尔对急性心肌梗死PCI患者早期心绞痛的疗效及vWF、CD62P、GPⅡb/Ⅲa受体复合物的影响[J].中国现代医学杂志,2025,35(9):1-6,6.基金项目
黑龙江省自然科学基金(No:YQ2021H013) （No:YQ2021H013）
